RE:RE:RE:Second trancheBased on the latest research detailing RuvidarTM's success in the destruction of various viruses, the Company has gained consensus from the National Microbiology Laboratory to direct its research away from the Covid-19 virus vaccine to develop this technology for an avian influenza vaccine."
addition, when the human coronavirus was treated with RuvidarTM, the spike protein remained intact suggesting that inactivation of coronaviruses by RuvidarTM may be used as a vaccine.